SGLT-2i use before COVID-19 may reduce adverse outcomes in diabetes patients
Dec 07, 2022
SGLT-2is are associated with the lowest probability for adverse outcomes followed by glucagon-like peptide-1 receptor agonists and metformin.
Evidence updated on myocarditis after mRNA COVID-19 vaccination
Aug 02, 2022
The incidence of myocarditis is probably higher after vaccination with mRNA-1273 (Moderna) versus BNT162b2 (Pfizer) and lower with an increased interval between doses.
COVID-19 incidence not increased with corticosteroid injections
Jul 13, 2022
The incidence of COVID-19 was lower for adults receiving image-guided corticosteroid injections for pain management.
Severe COVID-19 rates low with monoclonal antibody therapy during delta surge
Jul 06, 2022
The rates of severe disease were low for high-risk patients with mild-to-moderate COVID-19 treated with antispike monoclonal antibodies.
Vaccination protects overweight, obese against severe COVID-19
Jul 01, 2022
Protection against severe COVID-19 was similar for those who were overweight or obese versus those at a healthy weight; lower protection was seen for those who were underweight.
Veterans report low rates of adverse events with mRNA vaccines
Jun 16, 2022
Rates were slightly higher at 42 days for those receiving the Pfizer versus Moderna vaccine.
Vaccination offers partial protection for postacute phase of COVID-19
May 31, 2022
Individuals with breakthrough infection have an increased risk for death and postacute sequelae compared with contemporary controls.
Adding pulse oximetry shows no benefit in COVID-19
Apr 13, 2022
No improvement was observed in patients using pulse oximetry added to standard monitoring.
Philadelphia becomes first U.S. city to bring back indoor mask mandate
Apr 12, 2022
Philadelphia has an automatic indoor mask mandate that kicks in whenever cases in the city rise to a “Level 2.”
Rising COVID-19 cases in U.S. not yet cause for alarm: Fauci
Apr 11, 2022
There are an average of 31,000 new cases a day nationwide, a 3% increase from two weeks ago.